Journal
AGEING RESEARCH REVIEWS
Volume 85, Issue -, Pages -Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.arr.2023.101861
Keywords
Ageing-associated renal fibrosis; Lipid metabolism; Lipoproteins; Lipidomics; Small molecule therapeutic agents; Transforming growth factor ?
Categories
Ask authors/readers for more resources
Fibrosis is a common feature of chronic diseases, and ageing is a major risk factor for fibrotic diseases. However, current therapies are limited and new treatments that specifically target the pathogenesis of fibrosis are urgently needed. This review discusses the role of lipids and lipidomics in the development of renal ageing and fibrosis, as well as the potential use of dyslipidaemia as a therapeutic target. The review also highlights the progress in research on small molecule therapeutic agents that modulate lipid metabolism to prevent and treat ageing and ageing-associated renal fibrosis.
Fibrosis is the ultimate pathological feature of many chronic diseases, and ageing a major risk factor for fibrotic diseases. Current therapies are limited to those that reduce the rate of functional decline in patients with mild to moderate disease, but few interventions are available to specifically target the pathogenesis of fibrosis. In this context, new treatments that can significantly improve survival time and quality of life for these patients are urgently needed. In this review, we outline both the synthesis and metabolism of lipids and lipoproteins associated with ageing-associated renal fibrosis and the prominent contribution of lipids and lipidomics in the discovery of biomarkers that can be used for the prevention, diagnosis, and treatment of renal ageing and fibrosis. Next, we describe the effect of dyslipidaemia on ageing-related renal fibrosis and the pathophysiological changes in the kidney caused by dyslipidaemia. We then summarize the enzymes, transporters, transcription factors, and RNAs that contribute to dysregulated lipid metabolism in renal fibrosis and discuss their role in renal fibrosis in detail. We conclude by discussing the progress in research on small molecule therapeutic agents that prevent and treat ageing and ageing-associated renal fibrosis by modulating lipid metabolism. A growing number of studies suggest that restoring aberrant lipid metabolism may be a novel and promising therapeutic strategy to combat ageing and ageing-associated renal fibrosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available